


PATENT
674519-2030**AMENDMENT**

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

In the Claims:

1. (Previously Presented) A compound having Formula VIII




Formula VIII

wherein G is H, OH or a hydrocarbyl group, and wherein R¹ is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group.

- 2-7. (Cancelled)

8. (Original) A compound according to claim 1 having Formula XII



Formula XII

PATENT
674519-2030

9. (Currently Amended) A compound according to claim 1 wherein the hydrocarbyl group is selected from the group consisting of ~~an optionally substituted hydrocarbon group~~, an optionally substituted alkyl group, an optionally substituted haloalkyl group, an aryl group, an alkylaryl group, an alkylarylalkyl group and an alkene group.

10-11. (Cancelled)

12. (Currently Amended) A compound according to claim 1 wherein ~~G or~~ the hydrocarbyl group is selected from the group consisting essentially of:

a C₁-C₁₀ alkyl group, a ~~C₁-C₆ alkyl group~~, a ~~C₁-C₃ alkyl group~~;
C₁-C₁₀ haloalkyl group, a ~~C₁-C₆ haloalkyl group~~, a ~~C₁-C₃ haloalkyl group~~;
C₁-C₁₀ bromoalkyl group, ~~C₁-C₆ bromoalkyl group~~, ~~C₁-C₃ bromoalkyl group~~;
~~-(CH₂)₁₋₁₀ aryl, -(CH₂)₁₋₁₀-Ph, (CH₂)₁₋₁₀-Ph-C₁₋₁₀ alkyl, -(CH₂)₁₋₅-Ph, (CH₂)₁₋₅-Ph-C₁₋₅ alkyl, -(CH₂)₁₋₃-Ph, (CH₂)₁₋₃-Ph-C₁₋₃ alkyl, -CH₂-Ph, -CH₂-Ph-C(CH₃)₃, -(CH₂)₁₋₁₀ cycloalkyl, -(CH₂)₁₋₁₀-C₃₋₁₀cycloalkyl, -(CH₂)₁₋₇-C₃₋₇cycloalkyl, -(CH₂)₁₋₅-C₃₋₅cycloalkyl, -(CH₂)₁₋₃-C₃₋₃cycloalkyl, -CH₂-C₃cycloalkyl~~; and,
an alkene, a C₁-C₁₀ alkene group, a ~~C₁-C₆ alkene group~~, a ~~C₁-C₃ alkene group~~.


13-17. (Cancelled)

18. (Original) A compound according to claim 1 wherein G is H.

19. (Original) A compound according to claim 1 wherein R¹ is a sulphonate group.

20. (Currently Amended) A compound according to claim 1 wherein R¹ or the sulphonate group is of the formula

PATENT
674519-2030




wherein R^4 and R^5 are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the alkylene or each alkyl or cycloalkyl or alkenyl or aryl optionally contains one or more hetero atoms or groups.

21. (Original) A compound according to claim 20 wherein at least one of R^4 and R^5 is H.

22. (Original) A compound according to claim 21 wherein R^4 and R^5 are H.


23. (Currently Amended) A compound according to claim 1 having Formula XII



Formula XII

wherein G is selected from H, OH, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ haloalkyl, $-(\text{CH}_2)_{1-10}\text{-aryl}$, $-(\text{CH}_2)_{1-10}\text{-cycloalkyl}$, and $\text{C}_1\text{-C}_{10}$ alkene;

wherein R^1 is OH or a sulphamate group of the formula



PATENT
674519-2030

wherein R⁴ and R⁵ are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the alkylene ~~or each alkyl or cycloalkyl or alkenyl or aryl~~ optionally contains one or more hetero atoms or groups.

24. (Original) A pharmaceutical composition comprising a compound according to claim 1 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

25-30. (Cancelled)

31. (Previously Presented) A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in claim 1; (b) determining whether one or more of said candidate compounds is/are capable of inhibiting steroid sulphatase activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting steroid sulphatase activity.

32. (Cancelled)

33. (Original) A compound identified by the method according to claim 31.

34-36. (Cancelled)

37. (Original) A pharmaceutical composition comprising the compound according to claim 33 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

38-54. (Cancelled)